Investment analysts at JPMorgan Chase & Co. initiated coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set a “neutral” rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on PGEN. HC […]
Precigen, Inc. (NASDAQ:PGEN – Get Rating) – Equities researchers at HC Wainwright dropped their Q2 2023 earnings per share (EPS) estimates for shares of Precigen in a research report issued to clients and investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of ($0.09) per […]
– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in.
Shares of Precigen, Inc. (NASDAQ:PGEN – Get Rating) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.34 and traded as low as $1.14. Precigen shares last traded at $1.18, with a volume of 980,821 shares trading hands. Analyst Ratings Changes PGEN has been the […]
GERMANTOWN, Md., May 3, 2023 /PRNewswire/ Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,. | May 3, 2023